Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis
Primary Purpose
Acute Bronchitis
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Acebrophylline
Sponsored by
About this trial
This is an interventional treatment trial for Acute Bronchitis
Eligibility Criteria
Inclusion Criteria:
- Male or female aged 19 to 65 years, inclusive
- Patients with acute bronchitis which is accompanied with a cough which includes sputum within 48 hours and has over 5 for Bronchitis severity score (BSS) at Screening
- Patients who agreed to participate clinical trial and sign on informed consent form
Exclusion Criteria:
- Patients who are suspicious or diagnosed for pneumonia
- Patients with chronic bronchitis, Chronic Obstructive Pulmonary Disease (COPD), bronchiolitis, asthma, bronchial asthma
- Patients with active infection who needs administration of antibiotics
- Patients with myocardial infarction, congestive heart failure
- Patients with renal disorder or liver disorder
- Patients with hypotension or hypertension
- Patients with history of epilepsy
- Patients with hyperthyroidism
- Patients with gastroduodenal ulcer
- Patients with sever hypoxemia
Patients who are in drug or therapy or planned to have;
- antibiotics, anti-virus, angiotensin converting enzyme (ACE) inhibitor and systemic or inhalation glucocorticosteroids: from 2 weeks prior to administration of investigational product to termination of clinical trial
- Angiotension II receptor blocker (ARB), secretolytics/mucolytics, expectorants, antitussives, a herb medicines which has antitussive or expectorant effect: from 2 days prior to administration of investigational product to termination of clinical trial
- Analgesics except acetaminophen, antihistamines, β2-agonists, bronchodilators which includes anticholinergic agents, xanthine derivatives, central nervous system stimulants, drug which is known for interaction between acebrophylline (cimetidine, alloprinol, oral anticoagulants, furosemide, reserpine, barbiturates, phenytoin) and symtomatic therapy for other therapy for acute bronchitis: whole period for clinical trial
- Smokers
- Patients who has history for drug hypersensitivity or allergic reaction in component of investigational product or similar drug
- Patients with pregnant and/or have breast feeding.
- Patients with no intention to use appropriate contraceptives or has a plan to become pregnant
- Patients who had an administrationb of other investigational product or medical device for clinical trial 4 weeks prior to participation of clinical trial
- Patients who are identified as inappropriate by other investigators to participate clinical trial
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Sulfolase CR (200mg, QD)
Sulfolase Capsule (100mg, BID)
Arm Description
for 7 days with or without meal
for 7 days with or without meal
Outcomes
Primary Outcome Measures
Change from Baseline in baseline to Day 7 for total number of Bronchitis Severity Score (BSS)
Secondary Outcome Measures
Change from Baseline in baseline to Day 7 for number of BSS per symptom
Response rate at Day 7
Full Information
NCT ID
NCT02792946
First Posted
June 3, 2016
Last Updated
June 15, 2017
Sponsor
Hyundai Pharmaceutical Co., LTD.
1. Study Identification
Unique Protocol Identification Number
NCT02792946
Brief Title
Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis
Study Type
Interventional
2. Study Status
Record Verification Date
June 2016
Overall Recruitment Status
Completed
Study Start Date
November 2015 (Actual)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
January 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hyundai Pharmaceutical Co., LTD.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Compare the efficacy and safety of surfolase CR tablet with surfolate capsule in patients with acute bronchitis
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Bronchitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
244 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sulfolase CR (200mg, QD)
Arm Type
Experimental
Arm Description
for 7 days with or without meal
Arm Title
Sulfolase Capsule (100mg, BID)
Arm Type
Active Comparator
Arm Description
for 7 days with or without meal
Intervention Type
Drug
Intervention Name(s)
Acebrophylline
Primary Outcome Measure Information:
Title
Change from Baseline in baseline to Day 7 for total number of Bronchitis Severity Score (BSS)
Time Frame
Baseline, At Day 7
Secondary Outcome Measure Information:
Title
Change from Baseline in baseline to Day 7 for number of BSS per symptom
Time Frame
Baseline, At Day 7
Title
Response rate at Day 7
Time Frame
Baseline, At Day 7
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female aged 19 to 65 years, inclusive
Patients with acute bronchitis which is accompanied with a cough which includes sputum within 48 hours and has over 5 for Bronchitis severity score (BSS) at Screening
Patients who agreed to participate clinical trial and sign on informed consent form
Exclusion Criteria:
Patients who are suspicious or diagnosed for pneumonia
Patients with chronic bronchitis, Chronic Obstructive Pulmonary Disease (COPD), bronchiolitis, asthma, bronchial asthma
Patients with active infection who needs administration of antibiotics
Patients with myocardial infarction, congestive heart failure
Patients with renal disorder or liver disorder
Patients with hypotension or hypertension
Patients with history of epilepsy
Patients with hyperthyroidism
Patients with gastroduodenal ulcer
Patients with sever hypoxemia
Patients who are in drug or therapy or planned to have;
antibiotics, anti-virus, angiotensin converting enzyme (ACE) inhibitor and systemic or inhalation glucocorticosteroids: from 2 weeks prior to administration of investigational product to termination of clinical trial
Angiotension II receptor blocker (ARB), secretolytics/mucolytics, expectorants, antitussives, a herb medicines which has antitussive or expectorant effect: from 2 days prior to administration of investigational product to termination of clinical trial
Analgesics except acetaminophen, antihistamines, β2-agonists, bronchodilators which includes anticholinergic agents, xanthine derivatives, central nervous system stimulants, drug which is known for interaction between acebrophylline (cimetidine, alloprinol, oral anticoagulants, furosemide, reserpine, barbiturates, phenytoin) and symtomatic therapy for other therapy for acute bronchitis: whole period for clinical trial
Smokers
Patients who has history for drug hypersensitivity or allergic reaction in component of investigational product or similar drug
Patients with pregnant and/or have breast feeding.
Patients with no intention to use appropriate contraceptives or has a plan to become pregnant
Patients who had an administrationb of other investigational product or medical device for clinical trial 4 weeks prior to participation of clinical trial
Patients who are identified as inappropriate by other investigators to participate clinical trial
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis
We'll reach out to this number within 24 hrs